Silk Microsphere Encapsulation via Lipid Template Freeze-Drying
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing silk fibroin microspheres face challenges in maintaining protein drugs in an active form during encapsulation and controlled release, often requiring harsh conditions that degrade the microspheres and result in larger sizes unsuitable for smaller drug molecules.
Innovation Solution
A method involving mixing silk fibroin with a lipid composition, lyophilizing the mixture, dehydrating it to induce β-sheet structures, and removing lipids to form microspheres that encapsulate therapeutic agents effectively, while maintaining their activity and controlling release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional spray-drying methods are used to prepare silk fibroin microspheres, then the microspheres can be formed, but harsh high temperature conditions degrade the microspheres and reduce their suitability for protein drug delivery
Solution Approach 1:
The patent changes the preparation parameters by using freeze-drying instead of spray-drying, operating at low temperatures (freezing conditions) rather than high temperatures. This parameter change eliminates thermal degradation while still forming microspheres through the freeze-drying process, making the method suitable for protein drug delivery.
Solution Approach 2:
The patent replaces the thermal field (heat) used in conventional spray-drying with a freezing field (cold). By using freeze-drying, the system substitutes thermal energy with freezing conditions to achieve microsphere formation without the harmful high temperature effects, thereby preserving protein drug activity.
2Ease of manufacture
If conventional methods are used to prepare silk fibroin microspheres, then the microspheres can be formed, but they have large sizes (above 100 μm) making them unsuitable for smaller drug molecules
Solution Approach 1:
The patent changes the formulation parameters by incorporating lipids into the silk fibroin solution before freeze-drying. This parameter change results in smaller microsphere sizes (below 100 μm) while maintaining ease of manufacture, making the microspheres suitable for encapsulating smaller drug molecules.
3Reliability
If silk fibroin is used for controlled drug delivery, then the microspheres can encapsulate drugs, but maintaining protein drugs in an active form during encapsulation and release remains challenging
Solution Approach 1:
The patent replaces harsh thermal processing with freeze-drying, substituting heat with freezing conditions. This substitution eliminates thermal inactivation of proteins while still achieving effective drug encapsulation, thereby maintaining protein drug activity throughout the process.
Solution Approach 2:
The patent changes the processing parameters to mild freeze-drying conditions instead of harsh heat treatment. This parameter change creates a gentle environment that preserves protein drug activity while still achieving reliable encapsulation and controlled release.
4Duration of action of moving object
If high silk crystallinity is induced to control drug release, then release can be retarded, but the release control becomes less suitable for proteins with short half-lives
Solution Approach 1:
The patent changes the crystallinity parameter by controlling the freeze-drying process to create moderate crystallinity levels. This parameter change provides flexible release control that can be adjusted to match different protein half-lives, making the system adaptable to various drug types while still achieving controlled release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the preparation of silk fibroin microspheres that encapsulate therapeutic agents in an active form, achieving controlled release and maintaining biological activity, with a smaller size and higher homogeneity, suitable for a wide range of drug molecules.
Implementation Method 1
combining the lyophilized material with a dehydration medium for a sufficient period of time to at least partially dehydrate the silk fibroin solution
Implementation Method 2
induce β-sheet structures in the silk fibroin
Implementation Method 3
lyophilizing the mixture
Data Source
AI summary
A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.